Nafamostat mesilate versus heparin for anticoagulation in ECMO after cardiac surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults requiring systemic anticoagulation while on VA- or VV-ECMO after cardiac surgery will be randomly assigned to receive either nafamostat mesilate or standard unfractionated heparin. The trial compares incidence of bleeding and thrombosis while keeping anticoagulation within target levels during ECMO support. Safety outcomes and complication rates will be recorded and compared between the two groups. The design aims to determine if nafamostat provides similar or improved anticoagulation with fewer bleeding events.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years old
2. VA-ECMO or VV-ECMO was accepted after cardiac surgery.
3. The ECMO treatment team believes that systemic anticoagulation is needed
4. Sign the informed consent form

Exclusion Criteria:

1. The researchers believe that there are other causes of active bleeding that are not suitable to participate in this study.
2. Long-term use of anticoagulants before establishment of ECMO
3. Antiplatelet drugs were used before the establishment of ECMO
4. Severe liver insufficiency
5. Connective tissue disease
6. There is a history of allergy to heparin or nemolastat mesylate.
7. Pregnant
8. Previous diagnosis of heparin-induced thrombocytopenia
9. Expect to die within 48 hours
10. ECPR

Where it's running

• Beijing Anzhen Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Xiaotong Hou, MD
• Email: xt.hou@ccmu.edu.cn
• Phone: 010-64456631

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Safety and performance of the Novalung kit and Xenios 2.0 during stationary use for patients on ECMO

  This observational study tests whether using the Novalung ultimate kit with Xenios 2.0 (and MultiSupport Ground) helps maintain blood oxygenation in adults on ECMO during hospital stay and ground transport.

  Recruiting at 3 sites Fresenius Medical Care Deutschland GmbH · Erfurt, Bavaria and 2 other locations · NCT07156669

• Using near apneic ventilation with ECMO for severe respiratory distress

  This study is testing if a new way of breathing support called near apneic ventilation can help patients with severe respiratory distress on ECMO recover better and faster than the usual care.

  Recruiting at 11 sites Phase 3 Assistance Publique - Hôpitaux de Paris · Bobigny and 10 other locations · NCT06814340

• Using cangrelor to improve outcomes in patients with cardiogenic shock on ECMO

  This study is testing if adding a medication called cangrelor can help patients in cardiogenic shock on ECMO have better outcomes while reducing bleeding risks during their treatment.

  Recruiting Phase 2 IRCCS San Raffaele · Milan, Italy · NCT06792643

• Investigating left ventricle unloading during extracorporeal life support

  This study looks at how different methods of relieving pressure on the heart can help patients on a special life support system called VA ECLS, especially those in serious heart trouble.

  Recruiting Maastricht University Medical Center · Maastricht · NCT06766006

• MiniLung petite kit for neonates and infants with severe respiratory or cardiac failure

  We will test whether the MiniLung petite kit with the Xenios console safely improves oxygenation, removes CO2, and stabilizes circulation in newborns and young infants (2–8 kg) with severe respiratory or cardiopulmonary failure.

  Recruiting at 2 sites Fresenius Medical Care Deutschland GmbH · Bonn, North Rhine-Westphalia and 1 other locations · NCT06750536

• RECOMMEND platform testing interventions for adults receiving ECMO

  This platform tests whether different treatments, such as liberal versus restrictive red blood cell transfusion strategies, help adults on ECMO survive and need less organ support and hospital resources by day 28.

  Recruiting Phase 3 Australian and New Zealand Intensive Care Research Centre · Camperdown, New South Wales and 2 other locations · NCT06526533

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.